M Papamichail
Overview
Explore the profile of M Papamichail including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papamichail M, Marmagkiolis K, Pizanias M, Koutserimpas C, Heaton N
Scand J Surg
. 2018 Sep;
108(3):194-200.
PMID: 30249173
Background And Aims: Patients with liver tumors involving the inferior vena cava have a poor outcome without surgery. Liver resection en bloc with inferior vena cava resection and reconstruction is...
2.
Papamichail M, Pizanias M, Heaton N
Eur J Pediatr
. 2017 Dec;
177(3):285-294.
PMID: 29243189
Conclusion: This article reviews the various types of congenital portosystemic shunts and their anatomy, pathogenesis, symptomatology, and timing and options of treatment. What is Known: • The natural history and...
3.
Mittendorf E, Ardavanis A, Symanowski J, Murray J, Shumway N, Litton J, et al.
Ann Oncol
. 2016 Apr;
27(7):1241-8.
PMID: 27029708
Background: AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776-790). Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor (GM-CSF) to be safe...
4.
Gritzapis A, Perez S, Baxevanis C, Papamichail M
Br J Cancer
. 2004 Dec;
92(1):72-9.
PMID: 15583693
Unfractionated peptides (MW: up to 10 kDa), derived from HLA-A2.1 positive (+) HER-2/neu-overexpressing primary tumour cell acid cell extracts (ACE), were successfully used to generate in vitro cytotoxic T lymphocytes...
5.
Sotiropoulou P, Perez S, Iliopoulou E, Missitzis I, Voelter V, Echner H, et al.
Br J Cancer
. 2003 Sep;
89(6):1055-61.
PMID: 12966425
HER-2/neu oncoprotein contains several major histocompatibility complex class I-restricted epitopes, which are recognised by cytotoxic T lymphocyte (CTL) on autologous tumours and therefore can be used in immune-based cancer therapies....
6.
Gritzapis A, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez S, et al.
Br J Cancer
. 2003 Apr;
88(8):1292-300.
PMID: 12698199
Chimeric receptors comprising of the T-cell receptor-zeta cytoplasmic signalling chain fused to an extracellular ligand-binding domain of a single-chain antibody (scFv) have served as effective tools for redirecting cytotoxic T...
7.
Zamai L, Canonico B, Gritzapis A, Luchetti F, Felici C, Della Felice M, et al.
J Biol Regul Homeost Agents
. 2003 Feb;
16(4):289-302.
PMID: 12597645
Several techniques have been proposed for flow cytometric evaluation of intracellular antigens. This approach is particularly important for detection at the single cell level of proteins which correlate to tumour...
8.
Gritzapis A, Dimitroulopoulos D, Paraskevas E, Baxevanis C, Papamichail M
Cancer Immunol Immunother
. 2002 Aug;
51(8):440-8.
PMID: 12202905
We have developed culture conditions for the efficient expansion of cytotoxic effector cells from peripheral blood mononuclear cells (PBMC) by the timed addition of cytokine-rich supernatants collected from allogeneic PBMC...
9.
Sotiriadou R, Perez S, Gritzapis A, Sotiropoulou P, Echner H, Heinzel S, et al.
Br J Cancer
. 2001 Nov;
85(10):1527-34.
PMID: 11720440
HER2/neu-derived peptides inducing MHC class II-restricted CD4+ T helper lymphocyte (Th) responses, although critical for tumour rejection, are not thoroughly characterized. Here, we report the generation and characterization of CD4+...
10.
Micksche M, Lynge E, Diehl V, Estape J, Vertio H, Faivre J, et al.
Bull Cancer
. 2001 Aug;
88(7):687-92.
PMID: 11495822
No abstract available.